عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

India Announces Four-member Crew for Space Mission

FILE PHOTO: Intuitive Machines' Odysseus spacecraft passes over the near side of the Moon following lunar orbit insertion on February 21, 2024, in this handout image released February 22, 2024. Intuitive Machines/Handout via REUTERS
FILE PHOTO: Intuitive Machines' Odysseus spacecraft passes over the near side of the Moon following lunar orbit insertion on February 21, 2024, in this handout image released February 22, 2024. Intuitive Machines/Handout via REUTERS
TT
TT

India Announces Four-member Crew for Space Mission

FILE PHOTO: Intuitive Machines' Odysseus spacecraft passes over the near side of the Moon following lunar orbit insertion on February 21, 2024, in this handout image released February 22, 2024. Intuitive Machines/Handout via REUTERS
FILE PHOTO: Intuitive Machines' Odysseus spacecraft passes over the near side of the Moon following lunar orbit insertion on February 21, 2024, in this handout image released February 22, 2024. Intuitive Machines/Handout via REUTERS

India on Tuesday introduced four crew members for its maiden 'Gaganyaan' space voyage, as it aims to become the world's fourth country to send a crewed mission into space just months after a historic landing on the south pole of the moon.
Gaganyaan, or "sky craft" in Hindi, is the first mission of its kind for India and will cost about 90.23 billion rupees ($1.1 billion). It involves the launch of a habitable space capsule over the next year to an orbit of 400 km (250 miles) and its return via a landing in the Indian Ocean.
Prime Minister Narendra Modi awarded the four crew members, all of them air force officers, "astronaut wings" at a space center in Thiruvananthapuram in Kerala state on Tuesday, in their first public appearance after months of rigorous training.
The four officers are Prashanth Balakrishnan Nair, Ajit Krishnan, Angad Pratap and Shubhanshu Shukla, a government statement said.
It was not clear if all four astronauts would be on board the mission, Reuters reported.
Gaganyaan is a "historic" achievement for India, Modi said on X and in a statement, coming four decades after air force officer, Rakesh Sharma, became the first Indian to travel to space - with a Soviet mission.
"Time is ours, countdown is ours and so is the rocket," Modi told space scientists.
Only the United States, Russia, and China have sent their own crewed missions into space.
Astronauts from more than three dozen other countries have made space trips aboard either US or Russian missions.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”